MSD discontinues two Phase III Keytruda trials New Strong Buy Stocks for August 29th [Yahoo! Finance]
Prelude Therapeutics Incorporated (PRLD)
Company Research
Source: Yahoo! Finance
The KEYNOTE-867 (NCT03924869) trial was evaluating Keytruda plus stereotactic body radiation therapy (SBRT) compared to placebo plus SBRT for the treatment of adult patients with unresected stage I or II non-small cell lung cancer (NSCLC). Based on the recommendation of an independent data monitoring committee (DMC), MSD said KEYNOTE-867 was being discontinued because Keytruda in combination with SBRT did not meet the study's primary endpoint of demonstrating improvement in event-free survival (EFS), or its secondary endpoint of improved overall survival (OS). MSD's data revealed that Keytruda in combination with SBRT was associated with higher rates of adverse events (AEs), including those leading to death, in comparison to SBRT and placebo. The Phase III KEYNOTE-630 trial (NCT03833167) was evaluating Keytruda for the adjuvant treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC). The DMC recommended axing this trial for ‘futility' in light of
Show less
Read more
Impact Snapshot
Event Time:
PRLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRLD alerts
High impacting Prelude Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
PRLD
News
- Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.MarketBeat
- Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies [Yahoo! Finance]Yahoo! Finance
- Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid MalignanciesGlobeNewswire
- Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit [Yahoo! Finance]Yahoo! Finance
- Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology SummitGlobeNewswire
PRLD
Earnings
- 11/6/24 - Beat
PRLD
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form SCHEDULE
- 2/5/25 - Form 4
- PRLD's page on the SEC website